FONdation pour le
DEveloppement de la
REcherche
PHARmaceutique

Système de management de la qualité
Certifié ISO 9001

Toulouse, November 26th 2020

STUDY 20 - 2794

TEST REPORT N° 20-1589

Standard NF EN 17272 (April 2020)
Antiseptics and chemical disinfectants - Methods of airborne room disinfection
By automated process
Determination of Virucidal Activity - Human Coronavirus 229E
Medical area
Clean condition

Promotor	OXY'PHARM 829 rue Marcel Paul 94500 CHAMPIGNY SUR MARNE
Test Laboratory	FONDEREPHAR Faculté des Sciences Pharmaceutiques 35 Chemin des Maraîchers 31062 TOULOUSE cedex 9

Dr. Laila HADDIOUI Assay Manager	Dr Jocelyne BACARIA Quality Manager

FONDEREPHAR - Faculté des Sciences Pharmaceutiques – 35, chemin des Maraîchers – 31062 TOULOUSE cedex 9 - Email : contact@fonderephar.com - www.fonderephar.com
Tél. +33 (0)5 62 25 68 60 - Fax. +33 (0)5 61 25 95 72 - Siret 328 649 538 000 27 - APE 7211Z - N° TVA : FR 80328649538 - Association Loi 1901 n° W313014489

1. Test Laboratory

Fondation pour le Développement de la recherche en Pharmacie (FONDEREPHAR)
Faculté des Sciences Pharmaceutiques, 35 chemin des Maraîchers 31062 Toulouse cedex 9, France

2. Identification of the aerial disinfection system

Product :	**NOCOLYSE® Neutral 6%**
Batch :	A281020N/1
Expiry date :	10/2022
Date of receipt :	November/03/2020
Internal code :	20-2794-1
Active Substance:	Hydrogen peroxide (6%)
Device :	**NOCOSPRAY**
Serial number :	172X731

Concentration of disinfectant in the room: 5 mL/m^3
One treatment - recovery of the discs after 2 hours waiting at the end of the diffusion.

Promotor :	OXY'PHARM
Storage conditions:	Ambiant temperature
Period of testing:	November 2020

3- Experimental conditions

3-1 Virus/Receiving cells

Virus

Name	Human Coronavirus 229E
Origin :	ATCC
ATCC reference:	VR-740
Batch number supplier:	58505270
Internal number Batch:	SS-2-280520 (passage N°2)

Receiving cells

Name	Vero cells
Origin :	ATCC
ATCC reference:	CCL-81
Batch number ATCC:	3372621
Internal number Batch:	WCB-141215 (passage N°30)

The selected tests surfaces are stainless steel discs, flats, corresponding to the requirements of paragraph 5.2.3.1 of the standard. The suppliers are MERCIER CLAUSSE.

3-3 Conditions of use of the device/product

- Room :



Relative humidit: start of test 55% - end of test 59% (requirements 40 - 80%).
Temperature: start of test 18.2°C - end of test 19.1°C (requirements 18 - 22°C).
Test room volume: 32m³

- Carriers placement :

The carriers were placed at a height of 1.31m, in a vertical position, towards the opposite side of the device

3-4 Interfering substance and culture media

-Interfering substance:	BSA fraction V at 0,3g/l (Batch N°345)
-Culture media:	EMEM (Batch N°2681)

4-1 Control of sensitivity of cells to virus

- Add one volume of solution S or PBS + one volume of cellular suspension at 2.10^5 cells/ml for one hour in water bath at 36°C±1°C
- The cells are centrifuged at 1600trs/min for 10 min and resuspended in culture media
- The virus is diluted from 1/10 to 1/10 on a 96-well microplate
- Add 100 µl of cell suspension treated (Solution S) or not treated (PBS control) to each well of the microplate
- Incubate for 72 hours

The difference of title reduction between cells treated by the solution S and cells treated by PBS shall be < 1 lg.

4-2 Control of efficiency for suppression of disinfectant activity

- Add 1 volume of BSA + 1 volume of virus suspension + 1 volume of solution S or distilled water
- Leave the mixture in the ice bath for 60 min at room temperature

5- Titration method

- Titrate the virus (method titration on cell in suspension) by following steps:
- Serial dilutions (1/10) are realized with culture medium in the glass tube
- Transfer 0,1 ml of each dilution into eight wells of a microplate plaque 96
- The last row of eight wells will receive 0,1 ml of culture medium (control untreated cells)
- Add 0,1 ml of cell suspension at 2.10^5cell/ml.
- Incubate for 72 hours at 36 ° C ± 1 ° C under 5% CO_2 ± 2%.
- The viral cytopathic effect is read by using an inverted microscope

The estimated of infectious unite is determined by method KARBER-SPAERMAN calculating the negative logarithm of 50% endpoint (lgDIC50) by the following formula:

lgDICT50 = negative logarithm of the highest concentration of virus - [(Sum of% affected to each dilution/100 - 0.5) X (lg dilution)]

Faculté des Sciences Pharmaceutiques - 35 Chemin des Maraîchers - 31062 TOULOUSE Cedex 09
Tél. 05 62 25 68 60 Fax. 05 61 25 95 72 Email. contact@fonderephar.com

Virus suspension title assay: lgDICT50 = 8.50
No cytotoxicity was observed on the carrier without treatment which has been pretreated with the aerial disinfection system according to treatment.

	Degree of cytopathogenic effect (lgDICT50)	Logarithmic reduction
Sensitivity of cells to virus		
- With treatment (S1)		
Carrier 1	8.38	
Carrier 2	8.13	
Average	8.26	Difference <1 lg.
- Without traitement (S2)	8.63	
Carrier 1		
Efficiency for suppression of disinfectant activity		
- With treatment (D1)	7.0	
Carrier1	7.63	
Carrier 2	7.32	Difference <0,5 lg.
Average		
- Without traitement (D2)	7.50	
Carrier 1		
Test control		
Carrier1	7.13	
Carrier 2	7.0	
Average	7.1	
Assay		
Support 1	2.50	
Support 2	2.88	**4.27**
Support 3	3.13	
Average	2.83	

7- Conclusion

According to the conditions of test for the standard NF EN 17272 (April 2020), the couple device/product: NOCOSPRAY N° serial 172X731/NOCOLYSE Neutral 6% - Batch N° A281020N/1 for a use in medical area under clean condition, shows a virucidal activity against Human Coronavirus 229 E (log reduction≥4), after treatment at 5 mL/m^3 and 2 hours waiting time.

FONDEREPHAR
Faculté des Sciences Pharmaceutiques - 35 Chemin des Maraîchers - 31062 TOULOUSE Cedex 09
Tél. 05 62 25 68 60 Fax. 05 61 25 95 72 Email. contact@fonderephar.com